BR9609882A - Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana - Google Patents

Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana

Info

Publication number
BR9609882A
BR9609882A BR9609882A BR9609882A BR9609882A BR 9609882 A BR9609882 A BR 9609882A BR 9609882 A BR9609882 A BR 9609882A BR 9609882 A BR9609882 A BR 9609882A BR 9609882 A BR9609882 A BR 9609882A
Authority
BR
Brazil
Prior art keywords
membrane vesicle
pathogen
administer
treat
host
Prior art date
Application number
BR9609882A
Other languages
English (en)
Inventor
Jagath L Kadurugamuwa
Terry J Beveridge
Original Assignee
Univ Guelph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Guelph filed Critical Univ Guelph
Publication of BR9609882A publication Critical patent/BR9609882A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6006—Cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR9609882A 1995-08-04 1996-08-02 Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana BR9609882A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US190395P 1995-08-04 1995-08-04
PCT/CA1996/000526 WO1997005899A2 (en) 1995-08-04 1996-08-02 Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same

Publications (1)

Publication Number Publication Date
BR9609882A true BR9609882A (pt) 1999-07-27

Family

ID=21698360

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9609882A BR9609882A (pt) 1995-08-04 1996-08-02 Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana

Country Status (5)

Country Link
EP (1) EP0841944A2 (pt)
AU (1) AU707131B2 (pt)
BR (1) BR9609882A (pt)
CA (1) CA2182637A1 (pt)
WO (1) WO1997005899A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1350507A1 (en) * 2002-04-04 2003-10-08 Applied NanoSystems B.V. Delivery of a substance to a pre-determinated site
EP1490028A1 (en) * 2002-04-04 2004-12-29 Applied NanoSystems B.V. Delivery of a substance to a pre-determined site
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
FR2859218A1 (fr) * 2003-08-25 2005-03-04 Centre Nat Rech Scient Microvesicules de membrane externe marquees, leur procede de production et leurs utilisations
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
WO2009130649A2 (en) * 2008-04-21 2009-10-29 Nanoxis Ab Plasma membrane vesicles and methods of making and using same
WO2011027971A2 (ko) 2009-09-01 2011-03-10 주식회사이언메딕스 장내 공생 세균유래 세포밖 소포체, 및 이를 이용한 질병모델, 백신, 후보 약물 탐색 방법, 및 진단 방법
WO2011027956A2 (ko) 2009-09-04 2011-03-10 주식회사이언메딕스 그람 양성 박테리아에서 유래한 세포밖 소포체 및 이를 이용한 질병 모델
JP6045499B2 (ja) * 2010-10-27 2016-12-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 赤痢菌リポ多糖及び外膜タンパク質を含む免疫原性組成物
EP3068426B1 (en) 2013-11-13 2020-02-12 University Of Oslo Outer membrane vesicles and uses thereof
WO2021031270A1 (zh) * 2019-08-22 2021-02-25 四川大学 细菌膜囊泡及其分离制备系统和方法
CN114364396B (zh) * 2019-08-22 2024-01-23 四川大学 铜绿假单胞菌疫苗在抗烧烫伤感染中的应用
CN112402601B (zh) * 2019-08-22 2022-09-13 四川大学 金黄色葡萄球菌膜囊泡及其制备方法与应用
CN112410240B (zh) * 2019-08-22 2022-10-18 四川大学 铜绿假单胞菌膜囊泡及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68921895T3 (de) * 1988-12-19 2003-05-22 American Cyanamid Co., Portland Meningococcales klasse i-aussenmembranprotein-vakzin.
AU7239191A (en) * 1990-01-25 1991-08-21 University Of Colorado Foundation, Inc., The Method for preventing immune suppression in trauma patients
SU1708351A1 (ru) * 1990-02-05 1992-01-30 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи Штамм бактерий SнIGеLLа SoNNeI используемый дл приготовлени живой вакцины против дизентерии Зонне
NL9002092A (nl) * 1990-09-25 1992-04-16 Nederlanden Staat Vaccin, geschikt voor de bestrijding van bordetella pertussis.
EP0564689B1 (en) * 1992-04-10 1997-07-23 SCHWEIZERISCHES SERUM- & IMPFINSTITUT BERN Recombinant live vaccines against Gram-negative enteric pathogens
WO1993022423A1 (en) * 1992-04-29 1993-11-11 Microcarb Inc. Nutrient phospholipids for pathogenic bacteria
WO1994004677A1 (en) * 1992-08-13 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services The use of cd4 plasma membrane vesicles (pmv) as a therapeutic agent for aids
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.

Also Published As

Publication number Publication date
WO1997005899A3 (en) 1997-05-29
WO1997005899A2 (en) 1997-02-20
AU707131B2 (en) 1999-07-01
AU6609596A (en) 1997-03-05
CA2182637A1 (en) 1997-02-05
EP0841944A2 (en) 1998-05-20

Similar Documents

Publication Publication Date Title
BR9609882A (pt) Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana
McCluskie et al. Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
Ulmer et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants
AU749282B2 (en) Immunostimulant emulsion
BR9909192A (pt) Preparações galênicas de meloxicam para administração oral
US4455142A (en) Method of coadministering an antigen and an immunopotentiator
JP2003514872A5 (pt)
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
BR0014281A (pt) Vacina contra vìrus de gripe intranasal
PT815235E (pt) Vacinas para peste
BRPI0010612B8 (pt) vacinas
DE68921389D1 (de) Influenzaimpfstoff und Adjuvanten.
NO20032438L (no) Ortosubstituerte og metasubstituerte bisarylforbindelser, fremgangsmåte forfremstilling derav, deres anvendelse som et medikament samtfarmasöytiske preparater inneholdende forbindelsene
BR9712518A (pt) Polipeptìdeo, molécula de dna, vetor de expressão, célula hospedeira, composição farmacêutica, vacina, proteìna de fusão, processo para detectar tuberculose em um paciente, e, kit diagnóstico
DE69115514T2 (de) Liposomenhaltige intranasale Impfstofformulierung
SE9703191L (sv) Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom
BR9815255A (pt) Toxina de botulismo modificada, vacina oralcontra o botulismo, vacina oral contra umantìgeno selecionado e método para ministraroralmente um agente terapêutico a um animal
AR012376A1 (es) Formulacion de gel para la aplicacion topica
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
DE69533128D1 (de) Pharmazeutische akzeptabel dnase zusammensetzung
FR2737721B1 (fr) Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
PT1165081E (pt) Processo para a preparacao de preparacoes farmaceuticas cintendo tolperisona, para administracao oral
FR2757169B1 (fr) Proteine de fusion comportant tout ou partie de la proteine pp65 de cmv humain, utile notamment dans la preparation d'un vaccin
KR101136107B1 (ko) 알킬포스파티딜콜린과 혼합된 백신 조성물

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements